The drug is not recommended for patients with impaired renal functions and contains a diuretic for water volume.  BD  

PARSIPPANY, N.J., July 26 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once-image daily for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics. Tribenzor is not indicated for initial therapy.(2)

Tribenzor combines three widely prescribed antihypertensive medications, each working in a different way, to lower blood pressure.(2) It combines the complementary actions of olmesartan medoxomil (which blocks angiotensin II receptors), amlodipine (which inhibits the entrance of calcium into the blood vessel walls), and hydrochlorothiazide (a diuretic which reduces water volume in the blood).(2) Together these three medications allow blood vessels to relax so that blood can flow more easily.(2)

FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure


Post a Comment

Google Analytics Alternative